Month: June 2024

From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was grandly held in Glasgow, UK, a city renowned for its historical significance. This year marks the 50th anniversary of EBMT, and the event gathered leading figures in the field of hematopoietic stem cell transplantation and over 6,000 hematology experts from around the world. The attendees reviewed the remarkable achievements in the fields of hematology and bone marrow transplantation over the past 50 years and explored forward-looking patient management strategies. At the conference, chimeric antigen receptor T-cell (CAR-T) therapy, a highlight of this meeting, showcased a series of breakthroughs in the treatment of multiple myeloma and lymphoma, attracting significant attention. This issue features a special invitation to Professor Jun Ma from the Harbin Institute of Hematological Oncology to provide an insightful interpretation of five major research studies in the field of CAR-T cell therapy. Here, we present a compilation of these insights for our readers.

The "2024 Nanjing Lymphoma Forum" was held in Nanjing from May 11-12, 2024. The conference, primarily conducted through in-person exchanges, invited renowned experts in the field of lymphoid tumors from both domestic and international arenas. Through lectures, case discussions, and other forms of interaction, the forum focused on the latest achievements and advancements in the basic and clinical aspects of international lymphoid tumors. The goal was to further enhance the overall level of lymphoma diagnosis and treatment in China. At the conference, Professor Donglu Zhao from the Harbin Hematology and Oncology Research Institute gave a detailed presentation on the "CSCO Lymphoma Diagnosis and Treatment Guidelines — Interpretation of the Key Points of the Burkitt Lymphoma Guidelines." For a deeper understanding of this topic, "Oncology Frontier - Hematology Frontier" has compiled the content for readers' reference.

The "2024 Nanjing Lymphoma Forum" was held in Nanjing from May 11-12, 2024. The conference, primarily conducted through in-person exchanges, invited renowned experts in the field of lymphoid tumors from both domestic and international arenas. Through lectures, case discussions, and other forms of interaction, the forum focused on the latest achievements and advancements in the basic and clinical aspects of international lymphoid tumors. The goal was to further enhance the overall level of lymphoma diagnosis and treatment in China. At the conference, Professor Donglu Zhao from the Harbin Hematology and Oncology Research Institute gave a detailed presentation on the "CSCO Lymphoma Diagnosis and Treatment Guidelines — Interpretation of the Key Points of the Burkitt Lymphoma Guidelines." For a deeper understanding of this topic, "Oncology Frontier - Hematology Frontier" has compiled the content for readers' reference.